Checkpoint Therapeutics Stock
Checkpoint Therapeutics Stock
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Checkpoint Therapeutics stock is not clear.
Based on the current price of 0.5 € the target price of 4 € shows a potential of 698.08% for Checkpoint Therapeutics which would more than double the current price.
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - | - | - | - |
| Biocryst Pharmaceuticals | 0.310% | 13.034% | 12.248% | -26.682% | -1.586% | -27.571% | -29.425% |
| Madrigal Pharmaceuticals inc. | -0.810% | -5.834% | -9.122% | 14.854% | -25.858% | 33.913% | 265.760% |
| Evolus Inc | -0.550% | 1.124% | -12.621% | -72.519% | -33.945% | -56.627% | -55.654% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $9.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat